[1] Thai NLB, Mai NY, Vuong NL, Tin NM, Karam D, Refaey MA, Shahin KM, Soliman AL, Al Khudari R, Thuan TM, Sabbah GM, El-Qushayri AE, Karimzadeh S, Hirayama K, Huy NT. Treatment for vestibular schwannoma:systematic review and single arm meta-analysis[J]. Am J Otolaryngol, 2022, 43:103337. [2] Ebner FH, Tatagiba M. Update on diagnostics and microsurgical treatment of vestibular schwannoma[J]. Nervenarzt, 2019, 90:578-586. [3] Carlson ML, Vivas EX, McCracken DJ, Sweeney AD, Neff BA, Shepard NT, Olson JJ. Congress of neurological surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas[J]. Neurosurgery, 2018, 82:E35-39. [4] Tan NC, Macfarlane R, Donnelly N, Mannion R, Tysome JR, Jefferies S, Bance M, Axon PR. A 2 and 5-year longitudinal analysis of 671 consecutive patients diagnosed with unilateral vestibular schwannoma[J]. Otol Neurotol, 2022, 43:702-708. [5] Khandalavala KR, Saba ES, Kocharyan A, Daher GS, Lohse CM, Marinelli JP, Carlson ML. Hearing preservation in observed sporadic vestibular schwannoma:a systematic review[J]. Otol Neurotol, 2022, 43:604-610. [6] Gurewitz J, Schnurman Z, Nakamura A, Navarro RE, Patel DN, McMenomey SO, Roland JT, Golfinos JG, Kondziolka D. Hearing loss and volumetric growth rate in untreated vestibular schwannoma[J]. J Neurosurg, 2021, 136:768-775. [7] Vergara Olmos G, Dabiri S, Rutka J. Editorial. Decision-making in the surgical management of a vestibular schwannoma:when timing is everything (cum sincere omnia)[J]. J Neurosurg, 2021.[Epub ahead of print] [8] Ismail O, Sobhy O, Assal S, Sanghera P, Begg P, Irving R. Comparing hearing outcomes in irradiated and conservatively managed vestibular schwannoma[J]. Otol Neurotol, 2022, 43:e374-381. [9] Neve OM, Jansen JC, Koot RW, Ridder M, Paul G van Benthem P, Stiggelbout AM, Hensen EF. Long-term quality of life of vestibular schwannoma patients:a longitudinal analysis[J]. Otolaryngol Head Neck Surg, 2022.[Epub ahead of print] [10] Savardekar AR, Terrell D, Lele SJ, Diaz R, Keesari PR, Trosclair K, Kosty J, Wang CJ, Gardner G, Guthikonda B. Primary treatment of small to medium (< 3 cm) sporadic vestibular schwannomas:a systematic review and meta-analysis on hearing preservation and tumor control rates for microsurgery versus radiosurgery[J]. World Neurosurg, 2022, 160:102-113.e12. [11] Conlan O, Kontorinis G. Long-term growth patterns of vestibular schwannomas after stereotactic radiotherapy:delayed re-growth[J]. Eur Arch Otorhinolaryngol, 2022, 279:4825-4830. [12] Umekawa M, Shinya Y, Hasegawa H, Kawashima M, Shin M, Katano A, Minamitani M, Kashio A, Kondo K, Saito N. Stereotactic radiosurgery ensures an effective and safe long-term control of Koos grade Ⅳ vestibular schwannomas:a single-center, retrospective, cohort study[J]. J Neurooncol, 2022, 159:201-209. [13] Yao L, Alahmari M, Temel Y, Hovinga K. Therapy of sporadic and NF2-related vestibular schwannoma[J]. Cancers (Basel), 2020, 12:835. [14] Teyateeti A, Graffeo CS, Perry A, Tryggestad EJ, Brown PD, Pollock BE, Link MJ. The effect of prescription isodose variation on tumor control and toxicities in stereotactic radiosurgery for sporadic vestibular schwannoma:propensity score-matched case-control study[J]. J Neurol Surg B Skull Base, 2021, 83:193-202. [15] Huang CY, Peng SJ, Wu HM, Yang HC, Chen CJ, Wang MC, Hu YS, Chen YW, Lin CJ, Guo WY, Pan DH, Chung WY, Lee CC. Quantification of tumor response of cystic vestibular schwannoma to Gamma Knife radiosurgery by using artificial intelligence[J]. J Neurosurg, 2021.[Epub ahead of print] [16] Killeen DE, Tolisano AM, Isaacson B, Kutz JW, Barnett S, Wardak Z, Hunter JB. Vestibular schwannoma tumor size and growth rate predict response with gamma knife stereotactic radiosurgery[J]. J Neurol Surg B Skull Base, 2020, 83:11-18. [17] Saraf A, Pike LRG, Franck KH, Horick NK, Yeap BY, Fullerton BC, Wang IS, Abazeed ME, McKenna MJ, Mehan WA, Plotkin SR, Loeffler JS, Shih HA. Fractionated proton radiation therapy and hearing preservation for vestibular schwannoma:preliminary analysis of a prospective phase 2 clinical trial[J]. Neurosurgery, 2022, 90:506-514. [18] Macielak RJ, Wallerius KP, Lawlor SK, Lohse CM, Marinelli JP, Neff BA, Van Gompel JJ, Driscoll CLW, Link MJ, Carlson ML. Defining clinically significant tumor size in vestibular schwannoma to inform timing of microsurgery during wait-and-scan management:moving beyond minimum detectable growth[J]. J Neurosurg, 2021.[Epub ahead of print] [19] Gadot R, Anand A, Lovin BD, Sweeney AD, Patel AJ. Predicting surgical decision-making in vestibular schwannoma using tree-based machine learning[J]. Neurosurg Focus, 2022, 52:E8. [20] Landry AP, Yang K, Wang JZ, Gao AF, Zadeh G. Outcomes in vestibular schwannoma treated with primary microsurgery:clinical landscape[J]. J Clin Neurosci, 2022, 96:138-146. [21] Bozhkov Y, Shawarba J, Feulner J, Winter F, Rampp S, Hoppe U, Doerfler A, Iro H, Buchfelder M, Roessler K. Prediction of hearing preservation in vestibular schwannoma surgery according to tumor size and anatomic extension[J]. Otolaryngol Head Neck Surg, 2022, 166:530-536. [22] Manzoor NF, Nassiri AM, Sherry AD, Dang S, Yancey KL, Monsour M, Perkins EL, Khattab MH, Thompson RC, O'Malley MR, Bennett ML, Rivas AC, Haynes DS. Predictors of recurrence after sub-total or near-total resection of vestibular schwannoma:importance of tumor volume and ventral extension[J]. Otol Neurotol, 2022, 43:594-602. [23] Byun J, Kim JH, Song SW, Kim YH, Hong CK, Kim JH. Fate of residual tumor after subtotal resection of a previously irradiated vestibular schwannoma:long-term follow-up of a single-institutional series[J]. World Neurosurg, 2022, 163:e207-214. [24] Troude L, Boucekine M, Balossier A, Baucher G, Lavieille JP, Régis J, Roche PH. Is salvage surgery for large vestibular schwannomas after failed gamma knife radiosurgery more challenging[J]? Neurosurg Rev, 2022, 45:751-761. [25] Preet K, Ong V, Sheppard JP, Udawatta M, Duong C, Romiyo P, Nguyen T, Kwan I, Yang I. Postoperative hearing preservation in patients undergoing retrosigmoid craniotomy for resection of vestibular schwannomas:a systematic review of 2034 patients[J]. Neurosurgery, 2020, 86:332-342. [26] Hunt AA, Cass ND, Coughlin A, Gubbels SP. Time-based assessment of hearing preservation rates after microsurgical resection of vestibular schwannomas:a systematic review[J]. Otol Neurotol, 2020, 41:679-685. [27] La Monte OA, Tawfik KO, Khan U, Schwartz M, Friedman R. Analysis of hearing preservation in middle cranial fossa resection of vestibular schwannoma[J]. Otol Neurotol, 2022, 43:395-399. [28] de Boer NP, Böhringer S, Koot RW, Malessy MJA, van der Mey AGL, Jansen JC, Hensen EF. A prediction model for recurrence after translabyrinthine surgery for vestibular schwannoma:toward personalized postoperative surveillance[J]. Eur Arch Otorhinolaryngol, 2022, 279:2905-2913. [29] Scheller C, Rampp S, Tatagiba M, Gharabaghi A, Ramina KF, Ganslandt O, Bischoff B, Matthies C, Westermaier T, Pedro MT, Rohde V, von Eckardstein K, Strauss C. A critical comparison between the semisitting and the supine positioning in vestibular schwannoma surgery:subgroup analysis of a randomized, multicenter trial[J]. J Neurosurg, 2019.[Epub ahead of print] [30] Wu X, Wang X, Song G, Li M, Hou C, Chen G, Guo H, Xiao X, Tang J, Lin Q, Bao Y, Liang J. The effects of different surgical positions (semi-sitting and lateral position) on the surgical outcomes of large vestibular schwannoma:study protocol for a randomized controlled trial[J]. Trials, 2022, 23:492. [31] Raza-Knight S, Chiuta S, Golash A, Gurusinghe N, Roberts G, Alalade AF. The role of endoscopy in the resection of sporadic vestibular schwannomas:a systematic review of surgical outcomes[J]. Otol Neurotol, 2022, 43:2-11. [32] Lucidi D, Fabbris C, Cerullo R, Di Gioia S, Calvaruso F, Monzani D, Alicandri-Ciufelli M, Marchioni D, Presutti L. Quality of life in vestibular schwannoma:a comparison of three surgical techniques[J]. Eur Arch Otorhinolaryngol, 2022, 279:1795-1803. [33] Jianqing C, Yongchuan C, Zhihua Z, Huan J, Zhaoyan W, Hao W. A microscope-assisted endoscopic transcanal transpromontorial approach for vestibular schwannoma resection:a preliminary report[J]. Eur Arch Otorhinolaryngol, 2022, 279:75-82. [34] Matsushima K, Kohno M, Ichimasu N, Nakajima N, Yoshino M. Preoperative facial nerve palsy in patients with vestibular schwannoma:clinical features and postoperative functional prognosis in a case series of 34 among 1228 consecutive patients[J]. Oper Neurosurg (Hagerstown), 2022, 22:14-19. [35] Ung TH, Inoue M, Marty E, Ward RC, Martinez-Perez R, Kunigelis KE, Arnone GD, Cass S, Youssef AS. Nervus intermedius outcomes after vestibular schwannoma surgery and radiosurgery:a single-institution experience[J]. World Neurosurg, 2022, 160:e328-334. [36] Egiz A, Nautiyal H, Alalade AF, Gurusinghe N, Roberts G. Evaluating growth trends of residual sporadic vestibular schwannomas:a systematic review and meta-analysis[J]. J Neurooncol, 2022, 159:135-150. [37] Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA. Multicenter, prospective, phase Ⅱ and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma[J]. J Clin Oncol, 2019, 37:3446-3454. [38] Shi J, Lu D, Gu R, Sun H, Yu L, Pan R, Zhang Y. Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas:a systematic review and meta-analysis[J]. Am J Otolaryngol, 2021, 42:103148. [39] Karajannis MA, Hagiwara M, Schreyer M, Haque S. Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma[J]. Neuro Oncol, 2019, 21:822-824. [40] Tamura R, Fujioka M, Morimoto Y, Ohara K, Kosugi K, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2[J]. Nat Commun, 2019, 10:5758. [41] Tamura R, Toda M. A critical overview of targeted therapies for vestibular schwannoma[J]. Int J Mol Sci, 2022, 23:5462. [42] He W, Shu W, Xue L, Wang Y, Chai Y, Wu H, Wang Z. Synergistic effect of erastin combined with nutlin-3 on vestibular schwannoma cells as p53 modulates erastin-induced ferroptosis response[J]. J Oncol, 2022:ID7507857. [43] Helbing DL, Schulz A, Morrison H. Pathomechanisms in schwannoma development and progression[J]. Oncogene, 2020, 39:5421-5429. [44] Hannan CJ, Lewis D, O'Leary C, Donofrio CA, Evans DG, Roncaroli F, Brough D, King AT, Coope D, Pathmanaban ON. The inflammatory microenvironment in vestibular schwannoma[J]. Neurooncol Adv, 2020, 2:vdaa023. [45] Nisenbaum E, Misztal C, Szczupak M, Thielhelm T, Peña S, Mei C, Goncalves S, Bracho O, Ma R, Ivan ME, Morcos J, Telischi F, Liu XZ, Fernandez-Valle C, Dinh CT. Tumor-associated macrophages in vestibular schwannoma and relationship to hearing[J]. OTO Open, 2021, 5:2473974X211059111. [46] Tamura R, Morimoto Y, Sato M, Kuranari Y, Oishi Y, Kosugi K, Yoshida K, Toda M. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas[J]. J Neurooncol, 2020, 146:265-273. [47] Sergi B, Balducci M, Paludetti G, Olivi A, Picciotti PM, De Corso E, Passali GC, Fetoni AR, Lucidi D. Decision making on vestibular schwannoma:lessons from a multidisciplinary board[J]. World Neurosurg, 2022, 157:e506-513. [48] Strauss C, Rampp S, Scheller C, Prell J, Strauss C, Doerfler A, Engelhorn T. Volumetry and surgical grading systems for vestibular schwannoma size assessment and their relationship to postoperative facial nerve function[J]. J Neurol Surg A Cent Eur Neurosurg, 2022, 83:39-45. |